Prophylactic doxycycline for travelers' diarrhea. Results of a prospective double-blind study of Peace Corps volunteers in Kenya.
We performed a randomized double-blind study to determine the efficacy of doxycycline (100 mg daily) in preventing travelers' diarrhea among 39 Peace Corps volunteers during their first five weeks in Kenya. The volunteers took either doxycycline or placebo for three weeks and were observed for an additional two weeks. Nine of 21 taking placebo and one of 18 taking doxycycline had travelers' diarrhea during the treatment period (P = 0.012). The protection seemed to persist for at least one week after the drug was stopped. Enterotoxigenic Escherichia coli was the only pathogen isolated from the placebo group, but was not detected in persons taking doxycycline. None of these organisms were resistant to doxycycline or tetracycline, whereas resistance to tetracyclines and other antibiotics was common among the nonenterotoxigenic Esch. coli. We conclude that doxycycline effectively prevented most episodes of travelers' dirrhea.
D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D004311:Double-Blind Method; D004318:Doxycycline / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004926:Escherichia coli / Q000302:isolation & purification; D005243:Feces / Q000382:microbiology; D006801:Humans; D007630:Kenya; D008875:Middle Aged; D014195:Travel
D000907:Antibodies, Bacterial; D004318:Doxycycline